{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.52","upperLimit":"1.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"1.1","value":"0.93"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"1.0","value":"0.53"},{"groupId":"OG003","lowerLimit":"0.52","upperLimit":"1.0","value":"1.0"},{"groupId":"OG004","lowerLimit":"0.48","upperLimit":"2.0","value":"1.0"},{"groupId":"OG005","lowerLimit":"0.5","upperLimit":"4.1","value":"1.0"},{"groupId":"OG006","lowerLimit":"0.50","upperLimit":"2.2","value":"0.77"},{"groupId":"OG007","lowerLimit":"0.48","upperLimit":"4.1","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"51"}],"units":"Participants"}],"description":"Tmax is the time to maximum (peak) drug serum concentration. Study drug was administered with 240 mL of water. Summary of Steady-State, Day 15, was evaluated by dosing regimen.","dispersionType":"Full Range","groups":[{"description":"INCB054329 Monotherapy","id":"OG000","title":"INCB054329 Monotherapy - 15 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG001","title":"INCB054329 Monotherapy - 15 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG002","title":"INCB054329 Monotherapy - 22.5 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG003","title":"INCB054329 Monotherapy - 30 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG004","title":"INCB054329 Monotherapy - 20 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG005","title":"INCB054329 Monotherapy - 22.5 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG006","title":"INCB054329 Monotherapy - 25 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG007","title":"INCB054329 Monotherapy - Overall Dosing Regimen"}],"paramType":"MEDIAN","populationDescription":"All enrolled patients who received at least 1 dose of study medication and provided at least 1 plasma sample were included.","reportingStatus":"POSTED","timeFrame":"Summary of steady-state PK parameters by dosing regimen at Day 15","title":"Time to Maximum Plasma Concentration (Tmax) Analysis of INCB054329","type":"SECONDARY","unitOfMeasure":"hour"}